Butein impairs the pro-tumorigenic activity of malignant pleural mesothelioma cells

Mario Cioce, Claudia Canino, Claudio Pulito, Paola Muti, Sabrina Strano, Giovanni Blandino

Research output: Contribution to journalArticle

Abstract

Chronic inflammation appears to be a driving force behind cancer progression. NFκB and STAT3 activation plays a pertinent role in this process by mediating chemoresistance and the acquisition of mesenchymal features of protumorigenic cells. Epidemiological data and experimental observations suggest that Malignant Pleural Mesothelioma (MPM) is a prototype of chronic inflammation-driven cancer. Chemoresistance is a major feature of MPM. Thus, this paper explores the effect of butein (3,4,2′,4′- tetrahydroxychalcone), a naturally occurring NFκB and STAT3 inhibitor, on the tumorigenic properties of MPM cells. MPM cells harbor high nuclear levels of NFκB and pSTAT3(Y 705). Butein inhibits pSTAT3(Y 705) phosphorylation, nuclear localization of NFκB and the physical interaction of NFκB and pSTAT3. This correlates with a downregulation of several genes involved in cancer progression (such as ICAM1, Vimentin, MMP9, Twist), of proangiogenic cytokines (VEGF) and of IL-6 and IL-8, key growth factors for MPM. Hence, butein inhibits the migration of MPM cells and strongly affects the clonogenicity of MPM cells in vitro. Finally, we show that the in vitro actions of butein translate into anticancer effects in vivo. In fact, butein treatment severely affects tumor engraftment and potentiates the anticancer effects of pemetrexed in mouse xenograft models. Butein does not significantly affect the viability of human, untransformed mesothelial cells in vitro nor does it affect survival of tumor-free mice in vivo. The possibility of using butein as an additional treatment to current MPM therapies is discussed here.

Original languageEnglish
Pages (from-to)132-140
Number of pages9
JournalCell Cycle
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Neoplasms
Pemetrexed
Inflammation
Malignant Mesothelioma
butein
Vimentin
Interleukin-8
Heterografts
Vascular Endothelial Growth Factor A
Interleukin-6
Intercellular Signaling Peptides and Proteins
Down-Regulation
Phosphorylation
Cytokines
Genes
In Vitro Techniques
Therapeutics

Keywords

  • Butein
  • Chemoresistance
  • Mesothelioma
  • NFκB
  • STAT3

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Developmental Biology
  • Medicine(all)

Cite this

Butein impairs the pro-tumorigenic activity of malignant pleural mesothelioma cells. / Cioce, Mario; Canino, Claudia; Pulito, Claudio; Muti, Paola; Strano, Sabrina; Blandino, Giovanni.

In: Cell Cycle, Vol. 11, No. 1, 01.01.2012, p. 132-140.

Research output: Contribution to journalArticle

Cioce, Mario ; Canino, Claudia ; Pulito, Claudio ; Muti, Paola ; Strano, Sabrina ; Blandino, Giovanni. / Butein impairs the pro-tumorigenic activity of malignant pleural mesothelioma cells. In: Cell Cycle. 2012 ; Vol. 11, No. 1. pp. 132-140.
@article{8b48e2896bfb44888782e4a03b5bdebb,
title = "Butein impairs the pro-tumorigenic activity of malignant pleural mesothelioma cells",
abstract = "Chronic inflammation appears to be a driving force behind cancer progression. NFκB and STAT3 activation plays a pertinent role in this process by mediating chemoresistance and the acquisition of mesenchymal features of protumorigenic cells. Epidemiological data and experimental observations suggest that Malignant Pleural Mesothelioma (MPM) is a prototype of chronic inflammation-driven cancer. Chemoresistance is a major feature of MPM. Thus, this paper explores the effect of butein (3,4,2′,4′- tetrahydroxychalcone), a naturally occurring NFκB and STAT3 inhibitor, on the tumorigenic properties of MPM cells. MPM cells harbor high nuclear levels of NFκB and pSTAT3(Y 705). Butein inhibits pSTAT3(Y 705) phosphorylation, nuclear localization of NFκB and the physical interaction of NFκB and pSTAT3. This correlates with a downregulation of several genes involved in cancer progression (such as ICAM1, Vimentin, MMP9, Twist), of proangiogenic cytokines (VEGF) and of IL-6 and IL-8, key growth factors for MPM. Hence, butein inhibits the migration of MPM cells and strongly affects the clonogenicity of MPM cells in vitro. Finally, we show that the in vitro actions of butein translate into anticancer effects in vivo. In fact, butein treatment severely affects tumor engraftment and potentiates the anticancer effects of pemetrexed in mouse xenograft models. Butein does not significantly affect the viability of human, untransformed mesothelial cells in vitro nor does it affect survival of tumor-free mice in vivo. The possibility of using butein as an additional treatment to current MPM therapies is discussed here.",
keywords = "Butein, Chemoresistance, Mesothelioma, NFκB, STAT3",
author = "Mario Cioce and Claudia Canino and Claudio Pulito and Paola Muti and Sabrina Strano and Giovanni Blandino",
year = "2012",
month = "1",
day = "1",
doi = "10/4161/cc.11.1.18474",
language = "English",
volume = "11",
pages = "132--140",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Butein impairs the pro-tumorigenic activity of malignant pleural mesothelioma cells

AU - Cioce, Mario

AU - Canino, Claudia

AU - Pulito, Claudio

AU - Muti, Paola

AU - Strano, Sabrina

AU - Blandino, Giovanni

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Chronic inflammation appears to be a driving force behind cancer progression. NFκB and STAT3 activation plays a pertinent role in this process by mediating chemoresistance and the acquisition of mesenchymal features of protumorigenic cells. Epidemiological data and experimental observations suggest that Malignant Pleural Mesothelioma (MPM) is a prototype of chronic inflammation-driven cancer. Chemoresistance is a major feature of MPM. Thus, this paper explores the effect of butein (3,4,2′,4′- tetrahydroxychalcone), a naturally occurring NFκB and STAT3 inhibitor, on the tumorigenic properties of MPM cells. MPM cells harbor high nuclear levels of NFκB and pSTAT3(Y 705). Butein inhibits pSTAT3(Y 705) phosphorylation, nuclear localization of NFκB and the physical interaction of NFκB and pSTAT3. This correlates with a downregulation of several genes involved in cancer progression (such as ICAM1, Vimentin, MMP9, Twist), of proangiogenic cytokines (VEGF) and of IL-6 and IL-8, key growth factors for MPM. Hence, butein inhibits the migration of MPM cells and strongly affects the clonogenicity of MPM cells in vitro. Finally, we show that the in vitro actions of butein translate into anticancer effects in vivo. In fact, butein treatment severely affects tumor engraftment and potentiates the anticancer effects of pemetrexed in mouse xenograft models. Butein does not significantly affect the viability of human, untransformed mesothelial cells in vitro nor does it affect survival of tumor-free mice in vivo. The possibility of using butein as an additional treatment to current MPM therapies is discussed here.

AB - Chronic inflammation appears to be a driving force behind cancer progression. NFκB and STAT3 activation plays a pertinent role in this process by mediating chemoresistance and the acquisition of mesenchymal features of protumorigenic cells. Epidemiological data and experimental observations suggest that Malignant Pleural Mesothelioma (MPM) is a prototype of chronic inflammation-driven cancer. Chemoresistance is a major feature of MPM. Thus, this paper explores the effect of butein (3,4,2′,4′- tetrahydroxychalcone), a naturally occurring NFκB and STAT3 inhibitor, on the tumorigenic properties of MPM cells. MPM cells harbor high nuclear levels of NFκB and pSTAT3(Y 705). Butein inhibits pSTAT3(Y 705) phosphorylation, nuclear localization of NFκB and the physical interaction of NFκB and pSTAT3. This correlates with a downregulation of several genes involved in cancer progression (such as ICAM1, Vimentin, MMP9, Twist), of proangiogenic cytokines (VEGF) and of IL-6 and IL-8, key growth factors for MPM. Hence, butein inhibits the migration of MPM cells and strongly affects the clonogenicity of MPM cells in vitro. Finally, we show that the in vitro actions of butein translate into anticancer effects in vivo. In fact, butein treatment severely affects tumor engraftment and potentiates the anticancer effects of pemetrexed in mouse xenograft models. Butein does not significantly affect the viability of human, untransformed mesothelial cells in vitro nor does it affect survival of tumor-free mice in vivo. The possibility of using butein as an additional treatment to current MPM therapies is discussed here.

KW - Butein

KW - Chemoresistance

KW - Mesothelioma

KW - NFκB

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=84855683113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855683113&partnerID=8YFLogxK

U2 - 10/4161/cc.11.1.18474

DO - 10/4161/cc.11.1.18474

M3 - Article

C2 - 22185775

VL - 11

SP - 132

EP - 140

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 1

ER -